7:44 am ET *Galapagos shares are trading lower after Gilead received a complete response letter from the FDA requesting data from two studies for Filgotinib before completing its review of the NDA and expressed concern about the benefit/risk profile. The two companies are collaborative partners in the global development and commercialization of Filgotinib in Rheumatoid Arthritis. Benzinga
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.